阿奇霉素联合热毒宁治疗肺炎支原体感染患儿血清炎性因子的影响分析  

Clinical efficacy of azithromycin combined with reduning in treatment of Mycoplasmapneumoniaeinfection in children and its influence on serum inflammatory factors

作　　者：王利玲[1] 杜琳麟 程申[1] 

机构地区：[1]浙江省中医院儿科,浙江杭州310018

出　　处：《中华医院感染学杂志》2014年第4期863-865,共3页Chinese Journal of Nosocomiology

基　　金：浙江省卫生厅基金资助项目(2013RCA03)

摘　　要：目的探讨临床中阿奇霉素联合热毒宁治疗肺炎支原体感染患儿的临床效果,提高治疗的安全性。方法选取2011年1月-2012年12月医院收治的80例肺炎支原体感染患儿为研究对象,将其按照随机数字表法分为对照组和研究组,每组各40例,对照组在常规治疗基础上给予阿奇霉素治疗,研究组在常规治疗基础上给予阿奇霉素联合热毒宁治疗,观察两组患儿的临床疗效和血清IL-6、IL-8和TNF-α的炎性因子的变化,数据资料均采取SPSS19.0统计软件进行分析。结果临床治疗总有效率研究组为95.0%,对照组为82.5%,研究组的临床治疗总有效率明显优于对照组,差异有统计学意义(P<0.05);治疗前研究组和对照组IL-6、IL-8和TNF-α比较差异无统计学意义;治疗后研究组和对照组IL-6、IL-8和TNF-α较治疗前均有明显的改善,且研究组改善程度明显的优于对照组,差异有统计学意义(P<0.05);不良反应发生率研究组为15.0%,对照组为20.0%,两组比较差异无统计学意义。结论临床中对于肺炎支原体感染患儿应用阿奇霉素联合热毒宁治疗效果显著,有效的调节炎性因子的水平,并提高患儿的免疫力、不良反应少、治疗安全性高,值得临床中应用与推广。OBJECTIVE To explore the clinical efficacy of azithromycin combined with reduning in treatment of Mycoplasma pneumoniae infection in children so as to improve the safety of treatment. METHODS Totally 80 children with Mycoplasma pneumoniae infection, who were treated in the hospital from Jan 2011 to Dec 2012, were enrolled in the study and randomly divided into the control group and the study group, with 40 cases in each, then the control group was treated with azithromycin on the basis of conventional treatment, while the study group was given azithromycin combined with reduning on the basis of conventional treatment; the clinical efficacy and the changes of such serum inflammatory factors as IL-6, IL-8, and TNF-of the two groups were observed, and the statistical analysis of the data was performed with the use of SPSS19.0 software. RESULTS The total effective rate of treatment was 95.0 in the study group, significantly higher than 82.5 //00 in the control group, the difference was statistically significant （P 0. 05） ; the difference in the serum IL-6, IL-8, or TNF-abefore the treatment between the two groups was not statistically significant; after the treatment, the serum IL-6, IL-8, or TNF-aof both the study group and the control group was significantly improved, and the improvement degree of the study group was significantly better than that of the control group, the difference was statistically significant （P% , 0.05） ; the incidence of adverse events was 15.0 in the study group, 20.0% in the control group, the difference between the two groups was not statistically significant. CONCLUSION Azithromycin combined with reduning can achieve significant clinical efficacy in treatment of Mycoplasma pneurnoniae infection in the children and effectively regulate the levels of inflammatory factors, with the incidence of adverse events low, safety of treatment high, andit is worthy to be promoted in the hospital.

关 键 词：肺炎支原体 感染 阿奇霉素 热毒宁 炎性因子 

分 类 号：R978.1[医药卫生—药品]